Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2021

BIOne 1250 Dual Bioprocess Control Station

Author(s)Distek, Inc

The next evolution of the BIOne Product Line provides the clear solution for upstream laboratories who seek to maximize process throughput when bench space is limited. The BIOne 1250 Dual Bioprocess Control Station maximizes the utility of its compact footprint, allowing end users simultaneous control of two independent Bioreactor or Fermentation systems from a single central tower. Both single-use and autoclavable vessels are available for inclusion within your own custom system configuration.

Distek, Inc.
121 North Center Drive
North Brunswick, NJ 08902
Tel. 732.422.7585 bione@distekinc.com www.distekinc.com


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.